Biomarkers in Pediatric Congenital Heart Disease and PAH
Biomarkers in Pediatric Congenital Heart Disease and PAH
Nowadays, biomarkers are broadly used in clinical practice. Blood-derived biomarkers fulfil
 an important role in the field of cardiology. However, most biomarkers have been investigated
 for adult left ventricular disease. In congenital heart diseases (CHD) and pulmonary arterial
 hypertension (PAH), which involves children and mostly the right ventricle, less is known
 about the clinical and predictive value of blood-derived biomarkers. Since the group of
 survivors of CHD and PAH is growing because of the improved techniques nowadays, development
 of better tools to maintain the quality of life for the longer term in these patients is
 urgently needed. Blood-derived biomarkers are minimally invasive biomarkers, are quantitative
 and have shown to be able to reveal pathological processes in an early stage. Hence,
 blood-derived biomarkers may be a good addition to current diagnostic means in CHD and PAH.

 Objective: The primary objective of this study is to investigate cross-sectionally the
 association between various emerging blood-derived biomarkers and right ventricular (RV)
 function:defined as tricuspid annular plane systolic excursion (TAPSE) measured with
 echocardiography, in children with (a history of ) an abnormally loaded, volume and/or
 pressure loaded, right ventricle associated with CHD and/or PAH.
OBJECTIVES:

 Primary Objective:

 The primary objective is to investigate cross-sectionally (at baseline and after one year)
 the association between various emerging blood-derived biomarkers and right ventricular (RV)
 function:defined as tricuspid annular plane systolic excursion (TAPSE) measured with
 echocardiography, in children with (a history of ) an abnormally loaded, volume and/or
 pressure loaded, right ventricle associated with CHD and/or PAH.

 TIME FRAME: Baseline and after one year.

 Secondary Objective:

 Furthermore, the investigators aim to explore:

 -  The stability, dynamic (treatment-induced) longitudinal changes of these biomarkers and
 their association with RV function (defined as TAPSE).

 -  The predictive value of these biomarkers measured at baseline with regard to various
 clinically relevant impaired RV functioning parameters (TAPSE, RV- Fractional area
 change , RV-Fractional shortening and RV function assessed with eyeballing) at long term
 follow-up.

 -  The predictive value of these biomarkers with regard to clinical outcome defined as the
 composite of mortality, hospitalization, and or heart/lung transplantation.

 STUDY POPULATION: All patients with (a history of) an abnormally loaded right ventricle
 associated with CHD and/or PAH who are followed in the Center of Congenital Heart Disease -
 University Medical Center Groningen (CHH-UMCG) from 01-12-2017 will be approached by letter
 and telephone to be included.

 STUDY PROCEDURES:

 1. The study is introduced to the patient and his/her parents/legal representatives by
 letter and telephone. When the patient or his/her parents/legal representatives are
 interested the researcher will ask them to sign informed consent papers. When the
 patient is admitted to the clinical ward or will come for his/her outpatient clinic
 visit the researcher will check if informed consent has been given. If informed consent
 has been given and the patient meets the inclusion criteria he/she will be included in
 the study.

 2. Study procedures with respect to primary comparison:

 Echocardiography will be performed in all included patients (100%) in context of
 standard care. Blood drawing in context of standard care or additional study purposes
 will be performed in all included patients (100%).

 3. Study procedures (all performed in context of standard care) with respect to secondary
 comparisons: Mortality will be assessed in all patients (±100%).Functional class will be
 clearly documented in most included patients (±80%).MRI will be performed in a
 subpopulation of included patients (±50%).CPET will be performed in a subpopulation of
 included patients (±40%). 6MWD will be performed in a subpopulation included patients
 (±30%).

 WITHDRAWAL OF INDIVIDUAL SUBJECTS: Subjects can leave the study at any time for any reason if
 they wish to do so without any consequences. The investigator can decide to withdraw a
 subject from the study for urgent medical reasons.

 REPLACEMENT OF INDIVIDUAL SUBJECTS AFTER WITHDRAWAL: Withdrawal before the first time point
 will result in exclusion. Withdrawal after the first time point will result in a smaller
 sample size regarding to follow up, but the data will still be used for the available time
 points.

 PREMATURE TERMINATION: premature termination has no influence on the patients.

 ADMINISTRATIVE ASPECTS, MONITORING AND PUBLICATION:

 1. In this study the data will be coded according to a protected key on the general Beatrix
 Children's Hospital (BKK)-disk. Data will be collected in RedCap or Utopia, which both
 meet the security requirements according to legislation described by BROK and UMCG.

 All included patients will get a study identification number: BioCHD001, BioCHD002, etc.
 The order will be in the order of the obtained informed consent. The key will be
 available at the general BKK-disk for above mentioned investigators and contains the
 original patient number (UMCG-number), study identification number (study ID), and study
 identification number of other studies the patient is involved in.

 Data entry will be based on information from Epic, Poliplus, ECHOPAC (for
 echocardiography) or Medis QMass (for MRI). The blood samples will be stored on study ID
 by the central laboratory and assessments of the blood-derived biomarkers will be
 performed by the central laboratory as well. Blood results will be communicated
 according to study ID.

 Data will be stored in the central laboratory until all the different assays have been
 run. Data will be kept 15 years after end-of-study. Conditions for long-term document
 storage will follow GCP, institutional and national guidelines.

 2. Monitoring and Quality Assurance : Monitoring will take place according to guidelines in
 Research Toolbox on UMCG-intranet.

 3. Annual progress report: The sponsor/investigator will submit a summary of the progress
 of the trial to the accredited METC once a year. Information will be provided on the
 date of inclusion of the first subject, numbers of subjects included and numbers of
 subjects that have completed the trial, serious adverse events/ serious adverse
 reactions, other problems, and amendments.

 4. Public disclosure and publication policy: This prospective study will be registered
 prospectively at the website www.toetsingonline.nl and clintrail.gov.

 The results of the study will be published without reservations at international conferences
 and will be submitted for publication in international "peer-reviewed" scientific journals.

 SAFETY REPORTING:

 1. Temporary halt for reasons of subject safety:

 In accordance to section 10, subsection 4, of the WMO, the sponsor will suspend the
 study if there is sufficient ground that continuation of the study will jeopardise
 subject health or safety. The sponsor will notify the accredited METC without undue
 delay of a temporary halt including the reason for such an action. The study will be
 suspended pending a further positive decision by the accredited METC. The investigator
 will take care that all subjects are kept informed.

 2. Adverse events (AEs) Reporting or recording of adverse events is not applicable in this
 observational follow up study.

 3. The current study is a observational, non-intervention, follow up study in a population
 that contains patients with possible SAEs as result of their (congenital) heart disease.
 Therefore, only SAE's resulting from extra blood withdrawals will be reported by the
 investigator to the sponsor without undue delay after obtaining knowledge of the events.

 The sponsor will report the SAEs that are a result of extra blood withdrawal through the web
 portal ToetsingOnline to the accredited METC that approved the protocol, within 7 days of
 first knowledge for SAEs that result in death or are life threatening followed by a period of
 maximum of 8 days to complete the initial preliminary report. All other SAEs, related to
 extra blood withdrawal, will be reported within a period of maximum 15 days after the sponsor
 has first knowledge of the serious adverse events.

 SAMPLE SIZE CALCULATION: In this study the investigators would like to identify blood-derived
 biomarkers for right ventricular disease in CHD and PAH. In this sample size calculation the
 investigators have to take into account all the known references of the to be tested
 biomarkers and that the levels of the biomarkers could differ with respect to age and gender.
 Previous research confirmed lower levels of specific biomarkers in children compared to
 adults. Published results concerns mostly significant results with respect to clinically ill
 versus clinically adapted patients. The investigators would like to look at the correlation
 between the level of blood-derived biomarkers and RV function. Based on the published results
 with respect to biomarkers in CHD, a correlation coefficient of (-)0.3 should be sufficient.
 TAPSE, gender and age are included as predictor variables. With a good prediction level this
 will give a sample size of 380.

 STATISTICAL ANALYSIS PLAN: For the cross-sectionally primary endpoint, the investigators will
 analyze the correlations of the level of serum biomarker withRV-function (defined as the
 echocardiographic measurement TAPSE), using Spearman partial correlation analyses, crude and
 adjusted for age and sex. Subsequently, linear regression analysis will be used to further
 explore the relationship between biomarkers with continuous RV function. This will be done at
 baseline and after one year.

 For the exploratory objectives, the stability of biomarkers in time will be assessed using
 intraclass correlation coefficients.Repeated measures linear mixed model techniques will be
 applied to explore changes of biomarkers and right ventricular function in time in which
 patients will be entered as the random component of the mixed model. Binary or multinominal
 logistic regression analysis will be used to assess the relationship between biomarkers and
 RV function impairment.

 Kaplan Meier and Cox regression analysis will be performed to compare (transplantation-free)
 survival of patients with high or low baseline biomarkers and to explore the predictive value
 of biomarkers on clinical outcome.

 Not normally distributed continous variables (e.g. biomarkers with skewed distribution) will
 be, if appropriate, log-transformed, prior to inclusion in the regression models.
Inclusion Criteria:

 -  Age 0-18 years

 -  Patients with Pulmonary Arterial hypertension: diagnosis confirmed according to the
 standards of the National Expertise Center for PH in childhood.

 -  Patients with CHD with an abnormally loaded right ventricle including tetralogy of
 Fallot (TOF), pulmonary (valve) stenosis (PS), pulmonary insufficiency (PI), atrial
 septal defect (ASD), ventricular septal defect (VSD) and total anomalous pulmonary
 venous return (TAPVR): diagnosis confirmed by echocardiography or cardiac MRI in
 UMCG-CCH.

 Exclusion Criteria:

 -  Age >18 years

 -  Not familiar with Dutch language

 -  Pregnant

 -  Concomitant musculoskeletal disease

 -  No echocardiography available within three months before or after blood collection

 -  Being under examination for non-diagnosed disease at time of investigation